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Abstract
Objective—To define pain and physical function cutpoints that would, coupled with structural
severity, define a surrogate measure of “need for joint replacement surgery,” for use as an
outcome measure for potential structure-modifying interventions for osteoarthritis (OA).
Methods—New scores were developed for pain and physical function in knee and hip OA. A
cross-sectional international study in 1909 patients was conducted to define data-driven cutpoints
corresponding to the orthopedic surgeons’ indication for joint replacement. A post hoc analysis of
8 randomized clinical trials (1379 patients) evaluated the prevalence and validity of cutpoints,
among patients with symptomatic hip/knee OA.
Results—In the international cross-sectional study, there was substantial overlap in symptom
levels between patients with and patients without indication for joint replacement; indeed, it was
not possible to determine cutpoints for pain and function defining this indication. The post hoc
analysis of trial data showed that the prevalence of cases that combined radiological progression,
high level of pain, and high degree of function impairment was low (2%–12%). The most
discriminatory cutpoint to define an indication for joint replacement was found to be [pain (0–100)
+ physical function (0–100) > 80].
Conclusion—These results do not support a specific level of pain or function that defines an
indication for joint replacement. However, a tentative cutpoint for pain and physical function
levels is proposed for further evaluation. Potentially, this symptom level, coupled with
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radiographic progression, could be used to define “nonresponders” to disease-modifying drugs in
OA clinical trials.
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For many years, there has been great interest in the scientific community, pharmaceutical
companies, and regulatory agencies in the development of drugs that might influence the
natural history of osteoarthritis (OA) by preventing, slowing, or reversing joint tissue
breakdown. These so-called disease-modifying OA drugs should be evaluated using primary
outcomes that reflect the disease’s natural history. It would be useful to identify a valid
dichotomous outcome measure that would reflect the natural history of OA. In particular,
candidacy for total joint replacement (TJR) is discussed as a “hard” outcome measure1.
Limitations exist, however, in the use of such an outcome, in particular in variability in the
decision to perform surgery1. It would therefore be of interest to obtain a modified outcome
measure, derived from “time to surgery” but avoiding some of its limitations. An alternative
is “time to fulfill the criteria for surgery.” This type of “surrogate hard endpoint” is widely
used in other specialties. For example, treatments for heart failure are evaluated based on
“time to fulfill criteria for heart transplant.” However, the main limitation for OA trials is
that no consensus exists, regarding when TJR should be proposed, that could be used for
clinical research purposes.
Thus, an international working group was created in 2004, under the auspices of the
international organizations Outcome Measures in Rheumatology Clinical Trials
(OMERACT) and Osteoarthritis Research Society International (OARSI), to evaluate the
issues related to severity of hip and knee OA1,2,3. The objective of the working group was to
create a composite index that could define states of OA severity. This surrogate marker
could then be used to evaluate treatment response to disease-modifying drugs in OA clinical
trials.
The aim of this article is to present the methodology used by the working group, and the
results of the exploratory analyses conducted on pain and function as predictors of fulfilling
criteria for TJR.
MATERIALS AND METHODS
This article will present an overview of the methods and results, partly detailed
elsewhere1,2,3,4,5,6,7,8,9,10,11.
Previous and Ongoing Work
Choice of domains and tools defining severity and essential in the decision to
implement surgery—During a meeting in Paris in December 2004, the members of the
working group discussed which domains are essential in defining OA severity and in
deciding to refer a patient for TJR. Based on their expertise and on an extensive literature
review1, the following 3 domains were selected: pain, functional status, and structural
damage. The consensus was to consider the level of pain and function at one point, and a
definition of radiological progression between 2 timepoints11. However, it was also planned
to analyze the effect of persistence of the pain/function levels. The final binary outcome
could then be used as a definition for “responders/nonresponders” in OA clinical trials.
Elaboration of tools to assess each domain—For each domain, one or several tools
were selected or created: for pain, the ICOAP score (intermittent and constant OA pain)4,5;
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and for physical function, the Hip Disability and Osteoarthritis Outcome Physical Function
Short-form (HOOS-PS) for hip and knee injury, and the Osteoarthritis Outcome Score
Physical Function Short-form (KOOS-PS) for the knee6,7,8.
For structural damage, it was decided to use minimal joint space width (JSW) on plain
radiographs9,10, and to define structural progression as progression beyond measurement
error11.
Cross-sectional study to determine cutpoints for pain and functional disability
—The objective of the study was to define cutpoints for both pain and functional disability
of sufficient magnitude that TJR may be indicated. To this end, a data-driven approach,
based on real patient data, was chosen. A large multicenter cross-sectional study was
performed to define cutpoint levels for pain and functional disability among patients with
hip or knee OA being evaluated by orthopedic surgeons for possible need of TJR. The full
report is in preparation.
Study design: This international observational cross-sectional study was conducted in the
orthopedics departments of tertiary-care and secondary-care centers in Europe, North
America, and Australia (12 centers). Study population: Consecutive outpatients with a
diagnosis of hip or knee OA consulting with an orthopedic surgeon in one of the
participating centers. Gold standard: Indication for TJR according to the orthopedic
surgeon’s opinion. Pain and functional disability: These were collected using the ICOAP
score for pain4,5; and for physical function, the HOOS-PS for hip and KOOS-PS for the
knee6,7,8. Statistical analysis: The distributions of the 2 variables were analyzed for both hip
and knee OA, according to the gold standard outcome (recommendation for TJR, yes/no)
and compared using Student’s t test or the Wilcoxon rank test. The ability of pain and
functional disability to predict the gold standard was assessed in a univariate manner by a
nonparametric receiver-operating characteristic curve and area under the curve was
calculated. To take radiographic severity into account, the analyses were stratified on
radiographic severity. The 75th percentile technique was also applied.
Current Study
Post hoc analysis of available trial data in knee and hip OA—A further step was
to assess cutpoints for pain and function, in existing randomized clinical trial datasets of
putative disease-modifying OA drugs. Thus, the prevalence of sustained high pain and
functional disability levels, in populations of patients with symptomatic hip/knee OA
participating in clinical trials, was assessed. Indeed, if such a criterion were to be used as a
primary outcome, the sample size would be heavily influenced by the prevalence of the
outcome. The full results from this study will be submitted as a separate publication.
Selection of trials: A call was sent out for available databases, to pharmacological
companies involved in OA trials. Criteria for study inclusion were: randomized controlled
trial in symptomatic knee or hip OA; included a placebo group; and where pain and function
and the radiological JSW of the index joint at baseline and after at least 1 year of treatment
were assessed. Data collected: The baseline characteristics of the patients (completers), the
radiological parameters (assessed quantitatively as millimeters on plain radiographs): JSW
at baseline, JSW at the end of the treatment period (final visit), smallest detectable
difference in radiographic assessment if available, and levels of pain and function were
collected for the placebo groups from each randomized controlled trial. Levels of pain and
function were collected at each visit, with normalization of the scales (whatever the
questionnaire used) from 0 = best to 100 = worst condition.
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Cutpoints tested for pain, function, and duration: Different sets of criteria potentially
defining sustained high pain and disability levels were derived from the previous study and
tested for feasibility (in terms of prevalence) and validity; these were:
A. Pain + Function ≥ 80 during at least 2 consecutive visits
B. Pain + Function ≥ 80 during at least 3 consecutive visits
C. Pain + Function ≥ 80 during at least 4 consecutive visits
D. Pain + Function ≥ 100 during at least 2 consecutive visits
E. Pain + Function ≥ 100 during at least 3 consecutive visits
F. Pain + Function ≥ 100 during at least 4 consecutive visits
G. [Pain ≥ 50 and Function ≥ 30] OR [Function ≥ 50 and Pain ≥ 30] during at least 2
consecutive visits
H. [Pain ≥ 50 and Function ≥ 30] OR [Function ≥ 50 and Pain ≥ 30] during at least 3
consecutive visits
I. [Pain ≥ 50 and Function ≥ 30] OR [Function ≥ 50 and Pain ≥ 30] during at least 4
consecutive visits.
Statistical analysis: The prevalence of subjects fulfilling each set of criteria was calculated
in each study to estimate feasibility. A priori, the final outcome defining a disease-
modifying drug nonresponder was thought to be represented by: “sustained high patient-
reported levels AND structural degradation,” therefore the clinical criteria were then
combined with structural degradation, defined as significant loss of JSW over the study
duration (either by loss of JSW ≥ 0.5 mm, or greater than or equal to the smallest detectable
difference). Face validity was also assessed (data not shown).
RESULTS
The main points of the meeting at OMERACT 10 included presentation of results and
discussions of future steps.
Previous and Ongoing Work
Elaboration of tools to assess pain and functional disability in lower limb OA
—For pain, a new questionnaire was developed, the ICOAP4,5. For physical function, 2 new
questionnaires, one for the hip and one for the knee, were developed: the HOOS-PS for the
hip and KOOS-PS for the knee6,7,8.
Cross-sectional study to determine cutpoints for pain and functional disability
—In all, 1909 patients were analyzed: 1130 knee OA and 779 hip OA. Patients with a
recommendation for TJR had higher pain and disability levels than those not recommended
for TJR; pooling knee/hip patients, mean pain was 55.5 (95% CI 54.2, 56.8) for those with
TJR recommendation versus 44.9 (95% CI 43.2, 46.6) for those without TJR
recommendation (p < 0.0001). Mean functional impairment was 59.8 (95% CI 58.7, 60.9)
for those with TJR recommendation versus 50.9 (95% CI 49.3, 52.4) for those without TJR
recommendation (p < 0.0001). However, due to high overlap in pain/function levels between
patients with and those without a recommendation for TJR, in the pooled hip/knee
population, it was not possible to determine relevant cutpoints for pain or function, defining
recommendation for TJR, even when taking into account the duration of the symptoms or
after stratifying on radiographic severity.
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The 75th percentile technique indicated that a cutoff of around 90 for the sum “pain +
function” (where both pain and function are on a 0–100 scale) had 75% sensitivity with 55%
specificity for the indication of TJR by the orthopedic surgeon.
Current Study. Post Hoc Analysis of Available Trial Data in Knee and Hip OA
Eight clinical trials representing 1379 patients were included in these
analyses12,13,14,15,16,17,18,19. Studies evaluated patients with hip (n = 2) or knee (n = 6) OA.
The followup duration varied between 104 and 156 weeks.
Among the 6 knee and 2 hip studies, 248 (22% of 1124) and 132 (51% of 255) patients,
respectively, had radiographic progression (defined by loss of JSW ≥ 0.5 mm over the study
period). Among the 9 clinical cutpoints tested, the one with the most patients fulfilling the
criteria (n = 486, 36%) was the least stringent (pain + function ≥ 80 at ≥ 2 visits) and the
one with the fewest patients fulfilling the criteria (n = 101, 7%) was among the most
stringent (pain + function ≥ 80 at ≥ 4 visits).
The prevalence of the combination of “sustained high pain/function levels” with
radiographic progression was assessed. When radiographic progression was added to the
clinical criteria, the prevalence of patients fulfilling the tentative definitions of
nonresponders ranged from 2% (n = 29) to 17% (n = 160) across different studies. An
exploratory analysis of sample size calculations of patients that would be needed assuming
the results from the different scenarios was also presented.
Discussions of the Special Interest Group (SIG) at OMERACT 10
At the SIG at OMERACT 10 at which the data were presented, the results of both the cross-
sectional and clinical trial data were extensively discussed by attendees. There was
discussion of a need for additional analysis of hip versus knee studies, and heterogeneity of
studies in terms of visit timing that would require additional analysis as part of a research
agenda.
DISCUSSION
This working group, under the aegis of OMERACT and OARSI, represents a large group of
international experts to propose a definition of severity in lower limb OA that would
correspond to a theoretical indication for TJR. Using existing study designs, few patients
demonstrate significant radiographic progression. The numbers of patients needed and time
to conduct a clinical trial with the “hard” outcome TJR is not feasible. Moreover, individual
variations among surgeons, patients, and other issues of access confound such a hard
outcome. Thus, a definition of “theoretical indication for TJR” could be used as an outcome
measure in potential disease-modifying trials in OA.
Consensus was reached regarding the most important domains to be entered in such a set of
criteria, namely pain, functional disability, and structural degradation. New questionnaires
were developed to assess pain and functional disability in lower limb OA. A large
international study was conducted to assess pain and function levels of patients against a
gold standard of patients truly recommended for TJR, in orthopedic surgeons’ clinics from
representative international centers. Finally, post hoc analyses were conducted in existing
randomized clinical trial databases from lower limb OA to assess the prevalence of patients
fulfilling different clinical scenarios.
The first conclusion of this work is that, indeed, among patients with hip and knee OA
referred to an orthopedic surgeon, the level of symptoms was higher among patients for
whom TJR was indicated by the orthopedic surgeon. The second conclusion is that we could
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not find a cutpoint for pain and for physical disability (even when these levels were
maintained over time) that accurately discriminated, across different countries, patients who
did versus those who did not receive a TJR recommendation. The third conclusion is that the
prevalence of patients achieving different scenario cutpoints encompassing sustained
measures of pain and functional disability, with radiological progression, was low in
available databases.
Several studies have indicated discordance between radiographs and symptoms in lower-
limb OA20,21,22,23,24. In the cross-sectional study presented here, stratifying the analyses on
radiographic severity did not modify the conclusions. Interestingly, the results indicated a
stronger relationship between symptoms and surgical indication in hip OA than in knee OA.
The prevalence of subjects with sustained symptomatic OA of at least a moderate degree
with concomitant radiographic progression was low in the placebo arms of available
randomized clinical trial databases. Even using the most lenient criteria to define significant
persistent clinical symptoms, coupled with radiographic progression above measurement
error to represent a “virtual joint replacement indication,” large numbers of patients would
be required to detect differences between groups in potential disease-modifying trials.
The final proposal of the working group was that the cutoff corresponding to the less
stringent cutpoint (high sustained symptom level) of “pain + function > 80 during at least 2
consecutive visits AND radiological progression” should be further evaluated in clinical
trials. It will also be useful to obtain qualitative feedback from patients about this scenario.
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